<?xml version='1.0' encoding='utf-8'?>
<document id="23969513"><sentence text="Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel."><entity charOffset="68-79" id="DDI-PubMed.23969513.s1.e0" text="trastuzumab" /><entity charOffset="84-93" id="DDI-PubMed.23969513.s1.e1" text="docetaxel" /><pair ddi="false" e1="DDI-PubMed.23969513.s1.e0" e2="DDI-PubMed.23969513.s1.e0" /><pair ddi="false" e1="DDI-PubMed.23969513.s1.e0" e2="DDI-PubMed.23969513.s1.e1" /></sentence><sentence text="Pertuzumab is a novel antihuman epidermal growth factor receptor 2 (HER2) humanized monoclonal antibody" /><sentence text=" Combined with trastuzumab plus docetaxel, pertuzumab improved progression-free and overall survival versus trastuzumab plus docetaxel in the phase III CLEOPATRA trial (NCT00567190) in first-line HER2-positive metastatic breast cancer"><entity charOffset="32-41" id="DDI-PubMed.23969513.s3.e0" text="docetaxel" /><entity charOffset="43-53" id="DDI-PubMed.23969513.s3.e1" text="pertuzumab" /><entity charOffset="125-134" id="DDI-PubMed.23969513.s3.e2" text="docetaxel" /><pair ddi="false" e1="DDI-PubMed.23969513.s3.e0" e2="DDI-PubMed.23969513.s3.e0" /><pair ddi="false" e1="DDI-PubMed.23969513.s3.e0" e2="DDI-PubMed.23969513.s3.e1" /><pair ddi="false" e1="DDI-PubMed.23969513.s3.e0" e2="DDI-PubMed.23969513.s3.e2" /><pair ddi="false" e1="DDI-PubMed.23969513.s3.e1" e2="DDI-PubMed.23969513.s3.e1" /><pair ddi="false" e1="DDI-PubMed.23969513.s3.e1" e2="DDI-PubMed.23969513.s3.e2" /></sentence><sentence text=" Thirty-seven patients participated in a pharmacokinetic (PK)/corrected QT interval substudy of CLEOPATRA, which evaluated potential PK drug-drug interaction (DDI)" /><sentence text=" PK parameters were calculated using noncompartmental methods, and DDI analyses were carried out" /><sentence text=" In the presence of trastuzumab and docetaxel, the mean pertuzumab Cmin and Cmax in cycle 3 were 63"><entity charOffset="20-31" id="DDI-PubMed.23969513.s6.e0" text="trastuzumab" /><entity charOffset="36-45" id="DDI-PubMed.23969513.s6.e1" text="docetaxel" /><pair ddi="false" e1="DDI-PubMed.23969513.s6.e0" e2="DDI-PubMed.23969513.s6.e0" /><pair ddi="false" e1="DDI-PubMed.23969513.s6.e0" e2="DDI-PubMed.23969513.s6.e1" /></sentence><sentence text="6 and 183 Âµg/ml, respectively" /><sentence text=" The pertuzumab concentrations observed were consistent with simulations from a validated population PK model, indicating that trastuzumab and docetaxel did not alter pertuzumab PK"><entity charOffset="127-138" id="DDI-PubMed.23969513.s8.e0" text="trastuzumab" /><entity charOffset="143-152" id="DDI-PubMed.23969513.s8.e1" text="docetaxel" /><pair ddi="false" e1="DDI-PubMed.23969513.s8.e0" e2="DDI-PubMed.23969513.s8.e0" /><pair ddi="false" e1="DDI-PubMed.23969513.s8.e0" e2="DDI-PubMed.23969513.s8.e1" /></sentence><sentence text=" Comparison of geometric least-squares mean PK parameters between arms showed no impact of pertuzumab on the PK of trastuzumab or docetaxel"><entity charOffset="91-101" id="DDI-PubMed.23969513.s9.e0" text="pertuzumab" /><entity charOffset="115-126" id="DDI-PubMed.23969513.s9.e1" text="trastuzumab" /><entity charOffset="130-139" id="DDI-PubMed.23969513.s9.e2" text="docetaxel" /><pair ddi="false" e1="DDI-PubMed.23969513.s9.e0" e2="DDI-PubMed.23969513.s9.e0" /><pair ddi="false" e1="DDI-PubMed.23969513.s9.e0" e2="DDI-PubMed.23969513.s9.e1" /><pair ddi="false" e1="DDI-PubMed.23969513.s9.e0" e2="DDI-PubMed.23969513.s9.e2" /><pair ddi="false" e1="DDI-PubMed.23969513.s9.e1" e2="DDI-PubMed.23969513.s9.e1" /><pair ddi="false" e1="DDI-PubMed.23969513.s9.e1" e2="DDI-PubMed.23969513.s9.e2" /></sentence><sentence text=" In conclusion, no PK DDI was observed when pertuzumab, trastuzumab, and docetaxel were combined for the treatment of HER2-positive metastatic breast cancer"><entity charOffset="44-54" id="DDI-PubMed.23969513.s10.e0" text="pertuzumab" /><entity charOffset="56-67" id="DDI-PubMed.23969513.s10.e1" text="trastuzumab" /><entity charOffset="73-82" id="DDI-PubMed.23969513.s10.e2" text="docetaxel" /><pair ddi="false" e1="DDI-PubMed.23969513.s10.e0" e2="DDI-PubMed.23969513.s10.e0" /><pair ddi="false" e1="DDI-PubMed.23969513.s10.e0" e2="DDI-PubMed.23969513.s10.e1" /><pair ddi="false" e1="DDI-PubMed.23969513.s10.e0" e2="DDI-PubMed.23969513.s10.e2" /><pair ddi="false" e1="DDI-PubMed.23969513.s10.e1" e2="DDI-PubMed.23969513.s10.e1" /><pair ddi="false" e1="DDI-PubMed.23969513.s10.e1" e2="DDI-PubMed.23969513.s10.e2" /></sentence><sentence text=" " /></document>